A team at Kindai University in Osaka, Japan, fed ordinary L-arginine to fruit flies and mice engineered to develop ...

Dopamine could potentially treat Alzheimer’s by stimulating the production of an enzyme that breaks down beta-amyloid plaques, researchers say. Qi Yang/Getty Images When beta-amyloid plaques form, ...

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...

While scientists still do not fully know what causes Alzheimer’s disease, the current theories include the build-up of a protein called amyloid-beta in the brain. Now, researchers from the University ...

A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...

Researchers at Kindai University found that the amino acid L-arginine, costing about $2 a month, reduced amyloid-beta plaques in both fruit fly and mouse Alzheimer’s models. The orally administered ...

After studying 140,000 versions of the Aβ42 peptide, scientists identified some of the earliest molecular interactions that drive the formation of harmful amyloid protein aggregates found in Alzheimer ...

In the quest to cure Alzheimer's, the protein known as beta-amyloid has long taken center stage, driving development of a long list of drugs aimed at breaking up amyloid plaques in the brain. A team ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta plaques associated with Alzheimer's disease, performed so well in a phase Ib/IIa ...